AU2017311684B2 - Mesenchymal cell-derived exosomes to treat neurological disorders - Google Patents

Mesenchymal cell-derived exosomes to treat neurological disorders Download PDF

Info

Publication number
AU2017311684B2
AU2017311684B2 AU2017311684A AU2017311684A AU2017311684B2 AU 2017311684 B2 AU2017311684 B2 AU 2017311684B2 AU 2017311684 A AU2017311684 A AU 2017311684A AU 2017311684 A AU2017311684 A AU 2017311684A AU 2017311684 B2 AU2017311684 B2 AU 2017311684B2
Authority
AU
Australia
Prior art keywords
msc
mesenchymal stem
btbr
exosomes
saline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017311684A
Other languages
English (en)
Other versions
AU2017311684A2 (en
AU2017311684A1 (en
Inventor
Daniel Offen
Nisim PERETS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of AU2017311684A1 publication Critical patent/AU2017311684A1/en
Publication of AU2017311684A2 publication Critical patent/AU2017311684A2/en
Application granted granted Critical
Publication of AU2017311684B2 publication Critical patent/AU2017311684B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017311684A 2016-08-14 2017-08-14 Mesenchymal cell-derived exosomes to treat neurological disorders Active AU2017311684B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662374852P 2016-08-14 2016-08-14
US62/374,852 2016-08-14
PCT/IL2017/050899 WO2018033911A1 (en) 2016-08-14 2017-08-14 Mesenchymal cell-derived exosomes to treat neurological disorders

Publications (3)

Publication Number Publication Date
AU2017311684A1 AU2017311684A1 (en) 2019-03-07
AU2017311684A2 AU2017311684A2 (en) 2019-03-28
AU2017311684B2 true AU2017311684B2 (en) 2023-05-04

Family

ID=61196484

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017311684A Active AU2017311684B2 (en) 2016-08-14 2017-08-14 Mesenchymal cell-derived exosomes to treat neurological disorders

Country Status (10)

Country Link
US (2) US11129852B2 (cg-RX-API-DMAC7.html)
EP (1) EP3496730B1 (cg-RX-API-DMAC7.html)
JP (1) JP7014449B2 (cg-RX-API-DMAC7.html)
CN (1) CN109843305B (cg-RX-API-DMAC7.html)
AU (1) AU2017311684B2 (cg-RX-API-DMAC7.html)
ES (1) ES2925527T3 (cg-RX-API-DMAC7.html)
IL (1) IL264825B (cg-RX-API-DMAC7.html)
PL (1) PL3496730T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201901272WA (cg-RX-API-DMAC7.html)
WO (1) WO2018033911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11648260B2 (en) 2018-03-29 2023-05-16 Technion Research And Development Foundation Limitted Vesicles comprising a PTEN inhibitor and uses of same
CA3112505C (en) * 2018-09-20 2023-06-20 Citospin, S.L. Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same
EP3990625A4 (en) 2019-06-26 2023-07-19 Technion Research & Development Foundation Limited PRODUCTION OF EXTRACELLULAR VESICLES FROM STEM CELLS
JP6830286B1 (ja) 2020-06-26 2021-02-17 デクソンファーマシューティカルズ株式会社 精巣機能改善剤および精巣機能改善方法
US20230210910A1 (en) 2020-07-17 2023-07-06 Dexon Pharmaceuticals Inc. Method for preventing infection of a healthy person or a healthy animal with a virus that uses ace2 as a receptor, binding inhibitor and medical device
EP4212163A4 (en) 2020-09-08 2024-09-18 Dexon Pharmaceuticals Inc. CYTOKINE STORM INHIBITOR, METHOD FOR USING CYTOKINE STORM INHIBITOR, AND METHOD FOR SCREENING CYTOKINE INHIBITOR
JP6974892B1 (ja) 2021-05-27 2021-12-01 デクソンファーマシューティカルズ株式会社 癌悪液質の改善剤および癌悪液質の改善方法
JP7492757B2 (ja) 2022-03-22 2024-05-30 Ｄｅｘｏｎファーマシューティカルズ株式会社 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
US20250136992A1 (en) 2022-05-15 2025-05-01 Nurexone Biologic Ltd. Anti-pten rna interference oligonucleotides and uses thereof
CN115006427A (zh) * 2022-05-31 2022-09-06 尧舜泽生物医药(南京)有限公司 骨髓间充质干细胞外泌体在治疗帕金森病中的应用
EP4541359A1 (en) 2022-06-20 2025-04-23 Dexon Pharmaceuticals Inc. Ptx3 expression control agent, prophylactic drug or therapeutic drug for vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease, method for improving vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease
WO2023248844A1 (ja) 2022-06-20 2023-12-28 Ｄｅｘｏｎファーマシューティカルズ株式会社 Ｈｍｇｂ１の発現制御剤；急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法
CN120078807B (zh) * 2025-02-08 2026-03-31 广东省人民医院 改善卵巢功能的MSC-sEVs药物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156968A2 (en) * 2011-05-19 2012-11-22 Ariel - University Research And Development Company, Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
US20150079046A1 (en) * 2012-04-03 2015-03-19 Reneuron Limited Stem cell microparticles

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US20060188496A1 (en) * 2005-02-23 2006-08-24 Hanne Bentz Intranasal administration of active agents to the central nervous system
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
AU2009203638C1 (en) 2008-01-04 2013-07-25 Lydac Neuroscience Limited Microvesicles
EP2254586B1 (en) 2008-02-22 2015-04-08 Agency For Science, Technology And Research (A*star) Mesenchymal stem cell particles
KR20100054711A (ko) * 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
CN102596177B (zh) * 2009-07-01 2014-05-28 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用
JPWO2011118795A1 (ja) 2010-03-26 2013-07-04 国立大学法人名古屋大学 損傷部治療用組成物
JP5608927B2 (ja) * 2010-04-13 2014-10-22 国立大学法人名古屋大学 歯髄幹細胞を用いた神経疾患治療用組成物
GB201011589D0 (en) 2010-07-09 2010-08-25 Reneuron Ltd Therapeutic cells
WO2012020308A2 (en) * 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Cellular and molecular therapies
WO2012068170A2 (en) * 2010-11-15 2012-05-24 Jau-Nan Lee Generation of neural stem cells from human trophoblast stem cells
WO2013124817A2 (en) * 2012-02-22 2013-08-29 Brainstem Biotec Ltd. MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2013186735A2 (en) 2012-06-14 2013-12-19 Bar-Ilan Research And Development Company Ltd. Photothermal detection
WO2015038075A1 (en) * 2013-09-16 2015-03-19 Agency For Science, Technology And Research Method
WO2016149358A1 (en) 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156968A2 (en) * 2011-05-19 2012-11-22 Ariel - University Research And Development Company, Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
US20150079046A1 (en) * 2012-04-03 2015-03-19 Reneuron Limited Stem cell microparticles

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DOEPPNER, T. R. et al.: "Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic lmmunosuppression", Stem cells translational medicine, vol. 4, no. 10, (2015), pages 1131-1143, *
HADAR SEGAL-GAVISH ET AL: "Mesenchymal Stem Cell Transplantation Promotes Neurogenesis and Ameliorates Autism Related Behaviors in BTBR Mice : Mesenchymal stem cell transplantation", AUTISM RESEARCH, vol. 9, no. 1, (2015), pages 17 - 32, *
TOBER R. L., SMIRL A. L., BOGGESS T. F., ET AL.: "PIEZOREFLECTANCE AS A SUPPLEMENT TO PHOTOREFLECTANCE FOR NONDESTRUCTIVE CHARACTERIZATION OF GAAS/ALXGA1-XAS MULTIPLE QUANTUMWELLS.", JOURNAL OF APPLIED PHYSICS, AMERICAN INSTITUTE OF PHYSICS, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747, vol. 64., no. 09., 1 November 1988 (1988-11-01), 2 Huntington Quadrangle, Melville, NY 11747, pages 4678 - 4682., XP000029177, ISSN: 0021-8979, DOI: 10.1063/1.341251 *
XIN, H . et al.: Journal of Cerebral Blood Flow & Metabolism, vol. 33, no. 11, 21 August 2013 (2013-08-21), pages 1711-1715, DOI: doi:10.1038/jcbfm.2013.152 *
ZHUANG, X. et al.: "Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain", Molecular Therapy, vol. 19, no. 10, 13 September 2011 (2011-09-13), pages 1769-1779 *

Also Published As

Publication number Publication date
EP3496730A1 (en) 2019-06-19
EP3496730B1 (en) 2022-05-25
AU2017311684A2 (en) 2019-03-28
SG11201901272WA (en) 2019-03-28
JP7014449B2 (ja) 2022-02-01
AU2017311684A1 (en) 2019-03-07
JP2019524824A (ja) 2019-09-05
IL264825A (cg-RX-API-DMAC7.html) 2019-04-30
EP3496730A4 (en) 2020-05-06
CN109843305B (zh) 2023-03-10
US20210361717A1 (en) 2021-11-25
ES2925527T3 (es) 2022-10-18
CN109843305A (zh) 2019-06-04
US20190209621A1 (en) 2019-07-11
WO2018033911A1 (en) 2018-02-22
US11129852B2 (en) 2021-09-28
PL3496730T3 (pl) 2022-09-26
CA3033951A1 (en) 2018-02-22
IL264825B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
AU2017311684B2 (en) Mesenchymal cell-derived exosomes to treat neurological disorders
JP7707246B2 (ja) 幹細胞の培養及び治療のための培地、方法、細胞、及び分泌因子
Tajiri et al. Intravenous transplants of human adipose-derived stem cell protect the brain from traumatic brain injury-induced neurodegeneration and motor and cognitive impairments: cell graft biodistribution and soluble factors in young and aged rats
Peng et al. Microglia‐derived exosomes improve spinal cord functional recovery after injury via inhibiting oxidative stress and promoting the survival and function of endothelia cells
Bouchez et al. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease
US10870830B2 (en) Method for culturing differentiation-promoting and -sustaining spheroid form of tonsil-derived stem cells
Barreiro et al. Pivotal role for skin transendothelial radio-resistant anti-inflammatory macrophages in tissue repair
CA2960164A1 (en) Methods of producing and using exersomes and bioengineered exersomes
KR20160035087A (ko) 줄기 세포 마이크로입자 및 miRNA
JP2017526723A (ja) 移植片対宿主病（ｇｖｈｄ）または表皮水疱症（ｅｂ）のエキソソームによる治療方法
KR102213890B1 (ko) 엑소좀 기반의 면역세포의 교차분화 방법
EP3423070A1 (en) 3-d collagen scaffold-generated exosomes and uses thereof
Ge et al. Engineering EVs‐mediated mRNA delivery regulates microglia function and alleviates depressive‐like behaviors
US20240060048A1 (en) Method for promoting and improving properties of adipose tissue, tissue and cells obtained by said method
US20080075698A1 (en) Brain-Localizing Bone Marrow Progenitor cells
EP4180517A1 (en) Pre-conditioned mesenchymal stem cells and preparations and applications thereof
US20210238552A1 (en) Extracellular vesicles loaded with an exogenous molecule
CA3033951C (en) Mesenchymal cell-derived exosomes to treat neurological disorders
Yamazoe et al. Efficient generation of dopaminergic neurons from mouse embryonic stem cells enclosed in hollow fibers
JP2024529034A (ja) 尿由来幹細胞の培養のための培地組成物、これを用いた尿由来幹細胞の分離及び培養方法、腎臓疾患治療機能が向上した尿由来幹細胞及びこれを含む細胞治療剤組成物
US20250295699A1 (en) Methods and compositions for treating cortical hyperexcitability and reversing stroke-induced changes in gene expression and protein expression
CN115554316B (zh) SKP-SC-EVs在制备治疗帕金森病的产品中的应用
KR20250020300A (ko) 편도 유래 중간엽 줄기세포로부터 추출된 엑소좀을 함유하는 망막변성질환 예방 또는 치료용 조성물
RU2790031C2 (ru) Способ лечения аллергического заболевания дыхательных путей (AAD)/астмы
Zhang et al. Attenuating amyloid-beta pathology in mice with in situ programmed astrocytes

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 FEB 2019

FGA Letters patent sealed or granted (standard patent)